Warning Letter — Intas Pharmaceuticals Limited: Center for Drug Evaluation and Research (CDER)
The FDA issued a Warning Letter to Intas Pharmaceuticals Limited following an inspection by the Center for Drug Evaluation and Research (CDER). The letter identifies significant deviations from current good manufacturing practice (CGMP) for finished pharmaceuticals.
This affects Intas Pharmaceuticals Limited, specifically its drug manufacturing operations, quality management personnel, and regulatory compliance teams responsible for maintaining CGMP standards.
This indicates potential systemic failures in the manufacturer's quality control systems. A Warning Letter from CDER often suggests that the agency has found evidence of non-compliance that could jeopardize the safety or quality of drug products. For regulatory professionals, this signal may imply heightened scrutiny for other facilities under the same corporate umbrella and potential delays in pending product approvals until the issues are remediated.
Regulatory and Quality teams should conduct internal audits focused on the integrity of raw data and electronic records. Emphasis should be placed on ensuring that manufacturing documentation reflects actual floor activities and that oversight of site-level compliance is robust enough to detect systemic data discrepancies.
FDA issued a Warning Letter to Intas Pharmaceuticals Limited. Subject: Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/intas-pharmaceuticals-limited-721151-03302026
Open in openFDA / FDA.gov